WEE1 and neoplasm: Blocking the WEE1 pathway may help to empower tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors, as suggested by the association of selective, small molecule WEE1 inhibitor, adavosertib (AZD1775) and PD-L1 inhibitors, leading to tumour regression in murine models of SCLC [40].